120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于疾病阶段导向策略的治疗性纳米酶用于类风湿关节炎治疗
Authors Zhou Y , Yan H, Meng F, Zhang H, Tao X, Zhang Y, Li J, Yang Y, Liu K, Peng J, Peng Z
Received 16 October 2025
Accepted for publication 30 January 2026
Published 7 February 2026 Volume 2026:21 574600
DOI https://doi.org/10.2147/IJN.S574600
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Eng San Thian
Ye Zhou,1,* Heguo Yan,1,* Fanyu Meng,1,2,* Hengyan Zhang,3 Xingyu Tao,1 Yue Zhang,1 Jiaming Li,1 Yulian Yang,1 Kuncai Liu,1 Jiangyun Peng,1,4 Zining Peng1,2
1First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, People’s Republic of China; 2Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine, Kunming, People’s Republic of China; 3Department of Rheumatology, Zhaotong Hospital of Traditional Chinese Medicine, Zhaotong, People’s Republic of China; 4Department of Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiangyun Peng, Department of Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, People’s Republic of China, Email pengjiangyun@126.com Zining Peng, First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, People’s Republic of China, Email pzn2019@126.com
Abstract: Rheumatoid arthritis (RA) progresses through distinct pathophysiological states, transitioning from acute inflammatory phases with largely reversible tissue damage to chronic destructive stages characterized by irreversible structural alterations. Current therapeutic approaches largely employ uniform interventions without accounting for this disease heterogeneity, potentially compromising treatment efficacy. Dysregulated reactive oxygen species metabolism represents a mechanistic thread connecting RA stages. Acute inflammation is characterized by intense oxidative bursts, whereas chronic RA exhibits persistent oxidative stress, establishing a stage-dependent rationale for enzyme-based intervention. However, natural antioxidant enzymes are rapidly inactivated within the harsh inflammatory microenvironment, which is defined by acidic conditions and elevated proteolytic activity. Nanozymes are nanomaterials with enzyme-like catalytic activities, which overcome these limitations through enhanced environmental stability, tunable catalytic activity, and multifunctional integration. In contrast to prior nanozyme reviews that primarily organized discussions by material types or catalytic mechanisms, this review adopts a stage-oriented framework that aligns therapeutic strategies with the temporal evolution of RA pathophysiology. During acute inflammatory phases, nanozyme platforms integrate catalytic performance optimization, targeted delivery mechanisms, and synergistic anti-inflammatory interventions to rapidly neutralize oxidative stress and disrupt inflammatory cascades before irreversible damage occurs. In chronic destructive phases, therapeutic approaches combine sustained catalytic activity, precision targeting of established pathological structures, and multifunctional integration to concurrently suppress residual inflammation and promote tissue regeneration. This review compares nanozyme therapeutics with established RA treatments, including disease-modifying antirheumatic drugs and biological agents, to clarify their potential clinical positioning. Key challenges for clinical translation include long-term safety characterization; pharmacokinetic evaluation, particularly for intra-articular delivery; regulatory pathway development; and manufacturing scalability. Overall, this review establishes a stage-oriented nanozyme therapeutic framework aligned with RA progression patterns and provides translational guidance for developing nanozyme therapeutics tailored to individual pathological characteristics in RA management.
Keywords: Rheumatoid arthritis, nanozymes, reactive oxygen species, catalytic nanomaterials, precision medicine
1First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, People’s Republic of China; 2Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine, Kunming, People’s Republic of China; 3Department of Rheumatology, Zhaotong Hospital of Traditional Chinese Medicine, Zhaotong, People’s Republic of China; 4Department of Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiangyun Peng, Department of Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, People’s Republic of China, Email pengjiangyun@126.com Zining Peng, First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, People’s Republic of China, Email pzn2019@126.com
Abstract: Rheumatoid arthritis (RA) progresses through distinct pathophysiological states, transitioning from acute inflammatory phases with largely reversible tissue damage to chronic destructive stages characterized by irreversible structural alterations. Current therapeutic approaches largely employ uniform interventions without accounting for this disease heterogeneity, potentially compromising treatment efficacy. Dysregulated reactive oxygen species metabolism represents a mechanistic thread connecting RA stages. Acute inflammation is characterized by intense oxidative bursts, whereas chronic RA exhibits persistent oxidative stress, establishing a stage-dependent rationale for enzyme-based intervention. However, natural antioxidant enzymes are rapidly inactivated within the harsh inflammatory microenvironment, which is defined by acidic conditions and elevated proteolytic activity. Nanozymes are nanomaterials with enzyme-like catalytic activities, which overcome these limitations through enhanced environmental stability, tunable catalytic activity, and multifunctional integration. In contrast to prior nanozyme reviews that primarily organized discussions by material types or catalytic mechanisms, this review adopts a stage-oriented framework that aligns therapeutic strategies with the temporal evolution of RA pathophysiology. During acute inflammatory phases, nanozyme platforms integrate catalytic performance optimization, targeted delivery mechanisms, and synergistic anti-inflammatory interventions to rapidly neutralize oxidative stress and disrupt inflammatory cascades before irreversible damage occurs. In chronic destructive phases, therapeutic approaches combine sustained catalytic activity, precision targeting of established pathological structures, and multifunctional integration to concurrently suppress residual inflammation and promote tissue regeneration. This review compares nanozyme therapeutics with established RA treatments, including disease-modifying antirheumatic drugs and biological agents, to clarify their potential clinical positioning. Key challenges for clinical translation include long-term safety characterization; pharmacokinetic evaluation, particularly for intra-articular delivery; regulatory pathway development; and manufacturing scalability. Overall, this review establishes a stage-oriented nanozyme therapeutic framework aligned with RA progression patterns and provides translational guidance for developing nanozyme therapeutics tailored to individual pathological characteristics in RA management.
Keywords: Rheumatoid arthritis, nanozymes, reactive oxygen species, catalytic nanomaterials, precision medicine